

# CURRICULUM VITAE

Yoav Golan MD MS FIDSA

## A. PERSONAL INFORMATION:

Place of Work: Division of Geographic Medicine and Infectious Diseases, Department of Medicine, Tufts Medical Center

## B. EDUCATION:

1984-1987 BS, Hebrew University, Hadassah School of Medicine, Jerusalem, Israel  
1987-1990 MD, Hebrew University, Hadassah School of Medicine, Jerusalem, Israel  
2000-2002 MS, Clinical Research, Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA.  
2002 Certificate in Drug Development and Regulation, Tufts Center for the Study of Drug Development and the Drug Information Association (DIA), Boston, MA

## C. PROFESSIONAL TRAINING AND HOSPITAL APPOINTMENTS:

6/1991-5/1992 Rotating Internship, Hillel Yaffe Hospital, Hedera, Israel  
11/1992-10/1996 Medicine residency, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Israel  
11/1996-10/1998 Fellowship, Division of Infectious Diseases, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv, Israel  
11/1998-6/1999 Attending physician, Division of Infectious Diseases, Tel Aviv Sourasky Medical Center, Israel  
7/1999-6/2002 Clinical and research fellow, Division of Geographic Medicine and Infectious Diseases, New England Medical Center; Tufts University School of Medicine, Boston, MA  
6/2001-12/2014 Director, HIV care services, Suffolk County House of Corrections, Boston, MA  
7/2002- Attending physician, Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Tufts University School of Medicine, Boston, MA

## D. ACADEMIC APPOINTMENTS:

10/1996-6/1999 Instructor, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel  
7/2002-8/2011 Assistant Professor of Medicine, Tufts University School of Medicine, Boston, MA  
8/2011- Associate Professor of Medicine, Tufts University School of Medicine, Boston, MA

## E. HONORS AND AWARDS:

1996 The Yossufovic Foundation, Israel  
1996 Israel Board of Internal Medicine: Cum Laude  
1997 Tel Aviv University, Sackler School of Medicine, Schreiber Fund grant recipient  
1998 Israel Board of Infectious Diseases: Cum Laude  
2002 Partners HealthCare, Boston, MA: Excellence in Medicine Award  
2009 Clinical Infectious Diseases Outstanding Reviewer Award  
2014 Fellow, Infectious Diseases Society of America (FIDSA)

## F. LICENSURE AND CERTIFICATIONS:

1992 Medical Licensure, Israel # 26121  
1996 Israel Board of Internal Medicine # 15361  
1998 Israel Board of Infectious Diseases #16691  
1998 USMLE Parts 1 and 2. Permanent USMLE certificate  
2000 USMLE part 3.  
2001 Medical licensure, Massachusetts # 210052.

## G. TEACHING ACTIVITIES:

1985-1986 Teaching Assistant, Histology, Hadassah School of Medicine, Jerusalem, Israel.  
1995-1999 Internal Medicine and Infectious Diseases, 4<sup>th</sup> medical students, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.  
1999- Infectious Disease courses for medical students, Tufts University School of Medicine  
2002- Tufts Medical Center, morning report and noon conference presenter and preceptor  
2005- Tufts University School of Medicine, Clinical Pharmacology, Pathophysiology, Microbiology

## H. PROFESSIONAL ACTIVITIES:

2005-2016 Chair, CAP and Immunizations committee, Tufts Medical Center  
2007-2012 Member, Institutional Review Board, Tufts Medical Center and Tufts University School of Medicine  
2007-2012 Member, admissions committee, Tufts University School of Medicine.  
2007-2011 Member, Publications Committee, Infectious Diseases Society of America (IDSA)  
2009- Member, NIH Mycoses Study Group (MSG)

## I. MEMBERSHIP IN PROFESSIONAL SOCIETIES:

1999- Massachusetts Medical Society  
2000- Massachusetts Infectious Disease Society  
2000- American Medical Association  
2001- Infectious Disease Society of America  
2001- American Society for Microbiology  
2002- Society for Critical Care Medicine

## CURRICULUM VITAE

Yoav Golan MD MS FIDSA

2003- Society for Healthcare Epidemiology of America (SHEA)  
2007- Mycosis Study Group

### J. INDUSTRY POSITIONS:

2009- Medical Director, Delhaize America Vaccination Program. In 2019, the program delivered >450,000 vaccinations in supermarket-located pharmacies owned by Delhaze America. Delhaze owns more than 1500 mega supermarkets along the Eastern USA including Food Lyon, Sweetbay, Hannaford.  
2011-2014 Chief Scientific Officer, Profility Inc. Profility, in partnership with interRAI, advances customized healthcare using personalized predictions. Its first product for personalized long-term care placement is in the process of application in Belgium, in collaboration with the Belgian government.  
2013- Chief Executive Officer, ExArca. ExArca is a startup pharmaceutical company developing a novel agent to prevent and treat infections by *C. difficile* through preventing spore germination.  
2020- Chief Medical Office, Appili Therapeutics. Appili is a biotech company out of Halifax Nova Scotia with focus on the development of anti-infectives including favipiravir for COVID-19 and 2307, which is a novel antifungal for life-threatening invasive and resistant fungal infections.

### K. CONSULTANT: ANTI-INFECTIVE DEVELOPMENT AND IN-LICENSING

2005-2005 Salix Pharmaceuticals: anti-infectives for travellers diarrhea  
2005-8 XTL bio, NY, USA and Israel: in-licensing consultant  
2009- Cubist Pharmaceuticals, Lexington, MA, USA: Health Economics and Outcome Research, epidemiology, marketing  
2011-2011 Strategic Consultants International, London, UK: Perspectives on *C. difficile* Infections: Risk, Recurrence, and Refining Management  
2011- Forest Laboratories, NY, USA Pharmacoeconomics, Clinical trial design, Publications  
2011- Optimer Pharmaceuticals: - fidaxomicin development, HEOR, clinical trial design.  
2012-2012 Teva Pharmaceuticals: Anti-Infective Exploration Initiative  
2012-2012 Astra Zeneca, London, UK: Zinforo- from clinical trial to clinical practice  
2012-2012 United Biosource Corporation (UBC): Development of patient-reported outcome measures  
2015-2020 Appili Therapeutics

### L. ADVISORY BOARD MEMBER

2002- Cubist Pharmaceuticals, Lexington, MA, USA: Anti-Infective strategy, expansion, and clinical development  
2008- Merck & Co, PA, USA: Antifungal Development Advisory Board  
2010-2012 Pfizer Pharmaceuticals, NY, USA: Antibiotic Development  
2011-2015 Pfizer Pharmaceuticals: Global Vaccination Program.  
2011-2015 Forest Labs, NY, USA: Anti-Bacterial drug development  
2011-2013 Optimer Pharmaceuticals: Segmentation and risk stratification, predictive modeling  
2013-2014 Durata Therapeutics, Chicago, IL, USA: HEOR, business strategy  
2013-2015 DeNovaMed: Halifax, Canada: Development and targeting of novel antibiotics  
2014- Merck & Co, PA, USA: Executive Anti-Infective Development Board  
2014-2015 Theravance  
2015-2016 The Medicines Company: meropenem-vaborbactam development  
2016- Appilli Therapeutics, Halifax, Canada.  
2016- Shionogy: cefederocol development  
2016- Seres Therapeutics: Clostridium difficile prevention through Biome approaches  
2016- Achaogen: plazomicin development  
2017- Melinta Therapeutics: delafloxacin development.  
2017- Tetrphase pharmaceuticals: eravacycline development  
2018- Vedanta Biosciences: Microbiota-based solutions for *C. difficile* infections  
2019- Ferring: Microbiota-based solutions for *C. difficile* infections

### M. ADVISOR: VENTURE CAPITAL, FUNDS, THRUSTS (selected)

2007- Guidepoint Global  
2007- Coleman Research group  
2008-2008 Primary Experts LLC, NY, USA  
2009- HRA, LLC  
2010- Thompson Reuters  
2010- Canaccord Adams Investments  
2010- Grey Healthcare Group  
2011- 2011 PennSide Consulting  
2011- 2011 Cline, Davis, and Mann LLC  
2011- The Olson Research Group  
2011- Strategic Consultants International  
2011- 2011 Able Associates Research Group  
2012- The Tavistock Group  
2012-2012 Sudler & Hennessey, NY, NY  
2012-2012 John R. Lloyd & Associates, Benicia, CA, USA  
2014- Leerink Partners & MedaCorp, Boston, MA  
2014- McKinsey & Company

## CURRICULUM VITAE

Yoav Golan MD MS FIDSA

2014- Extera Partners, Boston, MA  
2014- Huron Consulting Group, NY, NY  
2014- Massachusetts Life Sciences Center

### N. PI, Recent Phase 2/3/4 RCTs

2006-9 OPT-80 vs vancomycin in adults with *C. difficile* infection. Phase 3, Optimer Pharmaceuticals,  
2008-10 A prospective, randomized trial comparing the efficacy of anidulafungin and voriconazole in combination to that of voriconazole alone when used for primary therapy in proven or probable invasive aspergillosis, Phase 4, Pfizer  
2008-10 A phase 2 multicenter, randomized, double-blinded, study to describe the safety, efficacy, and pharmacokinetics of daptomycin 10 mg/kg/day and vancomycin for the treatment of methicillin-resistant *Staphylococcus aureus* bacteremia, Cubist  
2009-11 A randomized, double-blinded, active-controlled, dose-ranging study of CB183,315 in patients with *Clostridium difficile* infection, Phase 2, Cubist  
2010-11 ACT-179811 in patients with *Clostridium difficile* infection, Phase 2, Actelion Pharmaceuticals  
2010-11 Multi-center, randomized, evaluator-blind, active-controlled, parallel-group design to determine safety, tolerability, and efficacy of multiple daily administration of LFF571 for 10 days in patients with moderate *Clostridium difficile* infections, Phase 2, Novartis  
2012-2015 A randomized, double-blinded, active-controlled, dose-ranging study of CB183,315 in patients with *Clostridium difficile* infection, Phase 3, Cubist  
2012- 2015 A Phase 3b Multi-Center, Double-Blind, Randomized, Placebo Controlled Study to Compare the Safety and Efficacy of Fidaxomicin for Prophylaxis against *Clostridium Difficile*-Associated Diarrhea in Individuals Undergoing Hematopoietic Stem Cell Transplantation, Phase 4, Optimer  
2012- 2015 MK-3415A Protocol 001 & 002 - Effectiveness of MK-3415A Given with SOC vs. Placebo in Patients Given SOC for CDI, Phase 3, Merck  
2012- 2016 A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients with Complicated Urinary Tract Infection. Phase 2, Merck  
2012- 2015 A Multicenter, Study to Describe the Safety and Efficacy of Ceftaroline Fosamil in Elderly Subjects with Community-Acquired Bacterial Pneumonia, Phase 4, Cerexa  
2012- 2015 A Multicenter, 2-Cohort Study to Describe the Safety and Efficacy of Ceftaroline Fosamil in Subjects with *Staphylococcus aureus* Bacteremia or With Persistent Methicillin-Resistant *Staphylococcus aureus* Bacteremia, Cerexa

### O. PEER REVIEWER

NIH Study Section, NIH Director's New Innovator Award Program (DP2), Clinical Infectious Diseases, Archives of Internal Medicine, Nature Reviews Microbiology, Drugs, American Journal of Kidney Diseases, Journal of Antimicrobial Chemotherapy, Value in Medicine, Critical Care Medicine, British Medical Journal, Critical Care, Mayo Clinic Proceedings, The International Journal of Infectious Diseases, American Journal of Infection Control, Medical Mycology, Scandinavian Journal of Infectious Diseases, Antimicrobial Agents and Chemotherapy, Transplantation, Anaerobe, Annals of Internal Medicine

### P. PUBLICATIONS

#### Chapters in Books:

1. Golan Y, Giladi M: Pre-travel consultation and vaccination. In: India Guide. Finley et al. Lonely Planet and Steinhart-Katzir publishers. 1996:104-25
2. Golan Y, Giladi M: Travelers' health. In: Latin America Guide. Finley et al. Lonely Planet and Steinhart-Katzir publishers. 1997:104-125.
3. Golan Y, Lai L, Hadley S: Candidiasis. In: Therapy of Infectious Diseases, Edited by Baddour and Gorbach. W.B. Saunders. 2002.

#### Original Articles:

1. Luchtman M, Golan Y, Heldenberg D, Kessler FB: Situs Inversus Abdominis in association with duodenal obstruction and internal hernia. Am J Perinatol 1993;10:255-7.
2. Shirihai H, Golan Y: First records of Long Tailed Shrike *Lanius schach* in Israel and Turkey. Sandgrouse 1994;16:36-40.
3. Schwartz D, Kornowski R, Schwartz IF, Dotan I, Wenrab B, Averbuch M, Golan Y, Levo Y, Iaina A: Prediction of renal impairment in elderly patients with congestive heart failure treated with Captopril. Cardiovasc Drugs Ther 1996;10:75-79.
4. Shapira I, Golan Y, Berger S, Giladi M: Japanese encephalitis- implications for travelers to the Far East. Harefuah 1996;130:406-408.
5. Avidor B, Kletter Y, Abulafia S, Golan Y, Ephros M, Giladi M: Molecular diagnosis of Cat Scratch Disease: a two-step approach. J Clin Microbiol 1997;35:1924-1930.
6. Golan Y, Poutsika DD, Tozzi S, Hadley S, Snyderman DR: Daptomycin for line-related *Leuconostoc* Bacteremia. J antimicrob chemother 2001;47:364-5.
7. Giladi M, Kletter Y, Avidor B, Metzker E, Varon M, Golan Y, Weinberg M, Riklis I, Ephros M, Slater L: Enzyme immunoassay for the diagnosis of Cat-Scratch Disease defined by polymerase chain reaction. Clin Infect Dis 2001;33:1852-1858.
8. Siegman-Igra Y, Levin R, Weinberger M, Golan Y, Schwartz D, Samra Z, Konigsberger H, Yinnon A, Rahav G, Keller N, Bisharat N, Karpuch J, Finkelstein R, Alkan M, Landau Z, Novikov J, Hassin D, Rudnicki C, Kitzes R, Ovadia S, Shimoni Z, Lang R, Shohat T: *Listeria monocytogenes* infection in Israel and review of cases worldwide. Emerging Infectious Diseases 2002;8:305-10.
9. Siegman-Igra Y, Fourer B, Orni-Wasserlauf R, Golan Y, Noy A, Schwartz D, Giladi M: Reappraisal of community-acquired bacteremia: a proposal of a new classification for the spectrum of acquisition of bacteremia. Clinical Infectious Diseases 2002 Jun 1;34(11):1431-9.
10. Ben-Ami R, Schnur LF, Golan Y, Jaffe CL, Mardi T, Zeltser D: Cutaneous involvement in a rare case of adult visceral leishmaniasis acquired in Israel. J Infect. 2002 Apr ;44(3):181-4.

## CURRICULUM VITAE

Yoav Golan MD MS FIDSA

11. Golan Y, Onn A, Avidor Y, Kivity S, Shapira I, Berger S, Giladi M: Asthma in adventure travelers; a prospective study evaluating the occurrence and risk factors for acute exacerbations. *Arch Intern Med* 2002 Nov 25;162(21):2421-6.
12. Golan Y, Snyderman DR: Reduced acquisition of VRE: gown effect or confounding? *Clinical Infectious Diseases* 2003;36(4):535-6.
13. Golan Y, McDermott LA, Jacobus NV, Goldstein EJ, Finegold S, Harrell LJ, Hecht DW, Jenkins SG, Pierson C, Venezia R, Rihs J, Iannini P, Gorbach SL, Snyderman DR: Emergence of Fluoroquinolones resistance among *Bacteroides* species. *Journal of Antimicrobials chemotherapy*, 2003;52(2):208.
14. Metzcor-Cotter E, Kletter Y, Avidor B, Varon M, Golan Y, Ephros M, Giladi M; Long-term serological analysis and clinical follow-up of patients with cat scratch disease. *Clinical Infectious Diseases*, 2003;37:1149-54.
15. Golan Y: Overview of transplant mycology. *Am J Health Syst Pharm*. 2005;62 Suppl 1:S17-21.
16. Golan Y, Doron S, Sullivan B, Snyderman DR: Transmission of a vancomycin-resistant *Enterococcus* in a Neonatal Intensive Care Unit (NICU). *The Pediatric Infectious Diseases Journal* 2005;24:566.
17. Golan Y, Wolf MP, Pauker SG, Wong JB, Hadley S: Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis. *Annals of Internal Medicine*, 2005;143:857-869.
18. Golan Y, Doron S, El Gamal H, Tanios M, Barefoot L, Blunt K, Bloom J, Gamson K, Snyderman LK, Elnekave E, Epstein S, Nasraway S, Snyderman DR: The Impact of Gown Use Requirement on Hand Hygiene Compliance. *Clinical Infectious Diseases*, 2006;42:370-6.
19. Golan Y, Wong JB, Pauker SG: Survivor costs in cost-effectiveness analysis? *Annals of Internal Medicine*, 2006;144:535.
20. Golan Y: Does chronic chorioamnionitis increases intrapartum HIV infection? *American Journal of Obstetrics and Gynecology*, 2006 July 3.
21. Liddicoat RV, Zheng H, Jeanne Internicola J, Werner BG, Arthur Kazianis A, Golan Y, Rubinstein EP, Freedberg KA, Walensky RP: Routine, Voluntary HIV Testing and Infectious Disease Seroprevalence in a Massachusetts Prison. *Journal of Urban Health*, 2006, August 8<sup>th</sup>.
22. McGovern B, Golan Y, Lopez M, Pratt D, Lawton A, Moore G, Epstein M, Knox T: The impact of cirrhosis on CD4+ T cell counts in HIV-seronegative patients. *Clinical Infectious Diseases*. 2007;44(3):431-7
23. Snyderman DR, Jacobus NV, McDermott LA, Ruthazer R, Golan Y, Goldstein EJ, Finegold SM, Harrell LJ, Hecht DW, Jenkins SG, Pierson C, Venezia R, Yu V, Rihs J, Gorbach SL.: National Survey on the Susceptibility of *B. fragilis*: Report and Analysis of Trends for 1997-2004: A US Survey. *Antimicrob Agents Chemother*. 2007 May;51(5):1649-55. Epub 2007 Feb 5
24. Sakoulas G, Golan Y, Lamp KC, Friedrich LV, Russo R: Daptomycin in the treatment of bacteremia. *Am J Med*. 2007 Oct;120(10 Suppl 1):S21-7.
25. Drees M, Snyderman DR, Schmid CH, Barefoot L, Hansjosten K, Vue PM, Cronin M, Nasraway SA, Golan Y: Prior Environmental Contamination Increases Risk for Acquisition of Vancomycin-Resistant Enterococci. *Clinical Infectious Diseases*, 2008 Mar 1;46(5):678-85
26. Chow J, Golan Y, Ruthazer R, Karchmer AW, Lichtenberg D, Chawla V, Janet Young J, Hadley S: Factors Associated with Non-albicans versus Albicans Candidemia in the Intensive Care Unit. *Clinical Infectious Diseases* 2008;46:April 16
27. Chow JC, Golan Y, Ruthazer R, Karchmer AW, Carmeli Y, Lichtenberg DA, Chawla V, Young JA, Hadley S: Risk factors for albicans and non-albicans candidemia in the intensive care unit. *Critical Care Medicine* 2008 Jul;36(7):1993-8.
28. Drees M, Snyderman DR, Schmid CH, Barefoot L, Hansjosten K, Vue PM, Cronin M, Nasraway SA, Golan Y: Antibiotic Exposure and Room Contamination Among Patients Colonized With Vancomycin-Resistant Enterococci. *Infection Control and Hospital epidemiology* 2008 Jul 16.
29. Golan Y: Empiric anti-Candida therapy for patients with sepsis in the ICU: how little is too little? *Critical Care* 2009;13:180. [Invited Editorial]
30. Marchaim D, Kaye K, Fowler VG, Anderson D, Chawla V, Golan Y, Karchmer A, Carmeli Y: Case-control study to identify factors associated with mortality among patients with methicillin-resistant *Staphylococcus aureus* bacteremia. *Clinical Microbiology and Infection* September 1<sup>st</sup> 2009
31. Chow JC, Golan Y: Vaccination of Solid-Organ Transplantation Candidates. *Clinical Infectious Diseases* 2009: Nov 15;49(10):1550-6. Invited Review.
32. Miller M, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK, Louie TJ. Opt80 Versus Vancomycin in *Clostridium difficile* Infection: Results of a Randomized Clinical Trial. *Gastroenterology* 2009, May, 136(5) A-116. DOI:10.1016/S0016-5085(09)60516-3.
33. Snyderman DR, Jacobus JV, McDermott LA, Golan Y, Hecht DW, Goldstein EC, Harrell L, Jenkins S, Newton D, Pierson C, Rihs J, Yu VL, Venezia R, Iannini P, Finegold SM, Gorbach S: Lessons Learned from the Anaerobe Survey: Historical Perspective and Review of the Most Recent Data 2005–2007. *Clinical Infectious Diseases* 2010 Jan 1;50 Suppl 1:S26-33.
34. Oxman D, Chow J, Frendl G, Hadley S, Hershkovitz S, Ireland P, McDermott LA, Tsai K, Marty F, Kontoyiannis DP, Golan Y: Candidaemia associated with decreased in vitro fluconazole susceptibility: is *Candida* speciation predictive of the susceptibility pattern? *Journal of Antimicrobial Chemotherapy* 2010.
35. Golan Y: ACP Journal Club. Decolonization of nostrils and skin of nasal carriers of *S. aureus* at admission prevented hospital-associated infection. *Annals of Internal Medicine* 2010 May 18;152(10):JC5-9. [Invited Commentary].
36. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach SL, Sears P, Shue YK: A randomized, double-blind clinical trial of Fidaxomicin versus vancomycin in *Clostridium difficile* infection. *New England Journal of Medicine* 2011 Feb 3;364(5):422-31
37. Lubin AS, Snyderman DR, Ruthazer R, Bide P, Golan Y: Predicting High Vancomycin MIC in Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infections. *Clinical Infectious Diseases* 2011;52(8):997–1002.
38. Snyderman DR, Jacobus NV, McDermott LA, Golan Y, Goldstein EJC, Harrell J, Jenkins S, Newton D, Pierson, C.7, Rosenblatt, J.8, Venezia, R.9, Gorbach, S.L.2, Queenan AM, Hecht DW: Update on Resistance of *B. fragilis* Group and Related Species with Special Attention to Carbapenems 2006-2009. *Anaerobe*. 2011;17(4):147-51.
39. Mullane KM, Miller MA, Weiss K, Lentnek A, Golan Y, Sears PS, Shue YK, Louie TJ, Gorbach SL: Efficacy of Fidaxomicin Versus Vancomycin as Therapy for *Clostridium difficile* Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections. *Clinical Infectious Diseases* 2011;53(5):440-7.
40. Kollef MH, Golan Y, Micek ST, Shorr AF, Restrepo MI. Appraising contemporary strategies to combat multidrug resistant gram-negative bacterial infections—proceedings and data from the Gram-Negative Resistance Summit. *Clinical Infectious Diseases* 2011;53 Suppl 2:S33-55
41. Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, Sears P, Gorbach S; OPT-80-004 Clinical Study Group. Fidaxomicin versus vancomycin for infection with *Clostridium difficile* in Europe, Canada, and the USA: a double-blind, non-inferiority, randomized controlled trial. *Lancet Infect Dis*. 2012 Apr;12(4):281-9. Epub 2012 Feb 8.
42. Epstein L, Golan Y. Fidaxomicin, a new treatment for *Clostridium difficile* infections. *Drugs of Today* 2012;48 (2):101-108.
43. Golan Y, Epstein L. Safety and efficacy of fidaxomicin in the treatment of *Clostridium difficile*-associated diarrhea (CDAD). *Therapeutic Advancements in Gastroenterology* September 2012

## CURRICULUM VITAE

Yoav Golan MD MS FIDSA

44. Miller M, Louie T, Mullane K, Weiss K, Lentnek A, Golan Y, Kean Y, Sears P. Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. *BMC Infect Dis.* 2013 Mar 25;13:148
45. Mullane K, Crook D, Cornely O, Golan Y, Louie T, Miller M, Josephson M, Gorbach G: Renal Impairment and Clinical Outcomes of Clostridium difficile Infection in Two Randomized Trials. *Am J Nephrol.* 2013;38(1):1-11
46. Weston A, Golan Y, Holcroft C, Snyderman DR: The Efficacy of Daptomycin vs. Vancomycin for MRSA Bloodstream Infection in Patients with Impaired Renal Function. *Clin Infect Dis.* 2014 Mar 18. [Epub ahead of print]
47. Golan Y: Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options. *BMC Infectious Diseases* 2015, 15:313.
48. Gardiner B, Golan Y: Ceftazidime-avibactam (CTZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections. *Expert Review of Anti-infective Therapy* 2016. DOI:10.1586/14787210.2016.1173542
49. Gabardi S, Martin S, Sura M, Golan Y: Micafungin Treatment and Eradication of Candiduria among Hospitalized Patients. *International Urology and Nephrology* 2016, DOI 10.1007/s11255-016-1410-0
50. Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, Jenkin G, Jensen W, Kim YS, Yoshida J, Gabryelski L, Pedley A, Eves K, Tipping R, Guris D, Kartsonis N, Dorr MB: MODIFY I and MODIFY II Investigators. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. *N Engl J Med.* 2017 Jan 26;376(4):305-317. doi: 10.1056/NEJMoa1602615 (in collaboration).
51. Vickers RJ, Tillotson GS, Nathan R, Hazan S, Pullman J, Lucasti C, Deck K, Yacyszyn B, Maliakkal B, Pesant Y, Tejura B, Roblin D, Gerding DN, Wilcox MH; Bhan A, Campbell W, Chopra T, Deck K, Golan Y, Gordon I, Kamepalli R, Khanna S, Lee C, Lucasti C, Maliakkal B, Minang I, Mullane K, Nathan R, Oughton M, Pesant Y, Phillips J, Pullman J, Riska P, Schrock C, Siegel J, Steinberg A, Talan D, Tamang S, Tan M, Weiss K, Wang C, Yacyszyn B, Young JA, Zenilman J.: Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study. *Lancet Infect Dis.* 2017 Jul;17(7):735-744. Doi: 10.1016/S1473-3099(17)30235-9. Epub 2017 Apr 28. (in collaboration).
52. Prabhu VS, Cornely OA, Golan Y, Dubberke ER, Heimann SM, Hanson ME, Liao J, Pedley A, Dorr MB, Marcella S; Thirty-day readmissions in hospitalized patients who received bezlotoxumab with antibacterial drug treatment for Clostridium difficile infection. *Clin Infect Dis Epub* 8/11/2017
53. Margoles L, DeNofrio D, Patel A, Golan Y, Vest A, Arkun K, Boucher H, Kiernan M, Upshaw J. Disseminated mucormycosis masquerading as rejection early after orthotopic heart transplantation. *Transpl Infect Dis.* 2018 Feb;20(1). doi: 10.1111/tid.12820.
54. Birch T, Golan Y, Rizzardini G, Jensen E, Gabryelski L, Guris D, Dorr MB. Efficacy of Bezlotoxumab Based on Timing of Administration Relative to Start of Antibacterial Therapy for Clostridium difficile Infection. *J Antimicrob Chemother.* 2018 Sep 1;73(9):2524-2528.
55. Basu A, Prabhu VS, Dorr MB, Golan Y, Dubberke ER, Cornely OA, Heimann SM, Pedley A, Xu R, Hanson ME, Marcella S. Bezlotoxumab is Associated with a Reduction in Cumulative Inpatient Days: Analysis of the Hospitalization Data from the MODIFY I and II Clinical Trials. *IN PRESS: Open Forum Infectious Diseases (OFID), 2018.*
56. Golan Y. Current Treatment Options for Acute Skin and Skin-Structure Infections: Perspectives of Hospital Clinicians. *Clin Infect Dis.* 2019 Apr 8;68(Supplement\_3):S206-S212. doi: 10.1093/cid/ciz004.
57. Perry W, Golan Y. A review on lefamulin in the treatment of community-acquired pneumonia. *Future Microbiology* June 2019
58. Golan Y, DuPont HL, Aldomiro F, Jensen EH, Hanson ME, Dorr MB. Renal Impairment, C. difficile Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data from Two Randomized Clinical Trials. *Open Forum Infectious Diseases, ofaa248, <https://doi.org/10.1093/ofid/ofaa248>.* 26 June 2020.
59. Golan, Y., Tang, Y., Mt-Isa, S. et al. Impact of Letermovir Use for Cytomegalovirus Prophylaxis on Re-Hospitalization Following Allogeneic Hematopoietic Stem Cell Transplantation: An Analysis of a Phase III Randomized Clinical Trial. *PharmacoEconomics Open* (2021). <https://doi.org/10.1007/s41669-021-00264-9>

### In Press

1.

### Articles Submitted for Publication:

1.

### Conference Presentations:

1. Giladi M, Avidor B, Kletter Y, Abulafia S, Golan Y, Ephros M: Evaluation of 3 Assays of DNA Amplification for the Diagnosis of Cat Scratch Disease. The 7th international Congress of Infectious Diseases, June 1996, Hong Kong.
2. Golan Y, Kletter Y, Kotter-Metzkor E, Giladi M: False Positive Serology in Recipients of Intravenous Gammaglobulins. The 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 1998, San Diego, CA
3. Giladi M, Abulafia S, Kletter Y, Orni-Wasserlauf R, Golan Y, Avidor B, Shalit I, Ephros M: Rifampin-Resistant Bartonella hensalae. Congress of Bartonella infections, February 1999, Tubingen, Germany
4. Poutsika DD, Golan Y, Tozzi S, Hadley S, Snyderman DR: Successful Treatment of Leuconostoc Species Bacteremia in Recipients of Bone Marrow Transplantation by Daptomycin. European Congress of Clinical Microbiology and Infectious Diseases, May 2000, Stockholm, Sweden
5. Golan Y, Levin R, Weinberger M, Schwartz D, Samra Z, Keller N, Shohat T, Siegman-Igra Y: Emergence of Listeria monocytogenes (Lm) in Israel (1995-1998). The 38th Annual Meeting of the Infectious Disease Society of America (IDSA), September 2000, New Orleans, LA
6. Jhamb-Regade N, Golan Y, Snyderman DR: Clinical Significance of Leuconostoc Spp, an Emerging Nosocomial Pathogen. The 39th Annual Meeting of the Infectious Disease Society of America (IDSA), October 2001, San Francisco, CA
7. Golan Y, Sullivan B, Snyderman DR: Elimination of Vancomycin-Resistant Enterococcus (VRE) Transmission in a Neonatal Intensive Care Unit (NICU). The 39th Annual Meeting of the Infectious Disease Society of America (IDSA), October 2001, San Francisco, CA
8. Golan Y, Jacobus NV, McDermott LA, Supran S, Hecht DW, Goldstein E, Venezia R, Harrell L, Jenkins S, Rihs J, Pierson C, Gorbach SL, Finegold S, Snyderman DR: Clindamycin Resistance (CR) Among Bacteroides fragilis Group (Bf): Analysis by Site of Infection. The 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), December 2001, Chicago, IL

## CURRICULUM VITAE

Yoav Golan MD MS FIDSA

9. Golan Y, Jacobus NV, McDermott LA, Supran S, Hecht DW, Goldstein E, Venezia R, Harrell L, Jenkins S, Rihs J, Pierson C, Gorbach SL, Finegold S, Snyderman DR: The Changing Epidemiology of Bacteroides Species (BSp) Infections in the US. The 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), December 2001, Chicago, IL
10. Slifkin M, Golan Y, Rutheizer R, Warshaw A, Freeman R, Fairchild R, Angelis M, Rohrer R, Barefoot L, Snyderman DR; Improved Cytomegalovirus (CMV) prevention is associated with increased survival in orthotopic liver transplantation (OLT). The 41 st Interscience Conference on antimicrobial agents and chemotherapy (ICAAC), December 2001, Chicago, IL
11. Golan Y, Wolf M, Pauker SG, Wong JB, Hadley S: Would empiric anti Candida (AC) therapy for selected ICU patients decrease mortality? Society of Critical Care Medicine 31st Congress, January 2002, San Diego, CA
12. Snyderman DR, Jacobus NV, McDermott LA, Golan Y, Rutheizaer and the National Survey Investigators: Analysis of In Vitro activity on newer fluoroquinolones against Bacteroides fragilis group as part of a national survey. Conference on Anaerobic Infections, June 2002, Salt Lake City, Utah
13. Golan Y, Wolf M, Pauker SG, Wong JB, Hadley S: Cost-effectiveness of empiric anti-Candida therapy for selected ICU patients. The 4th Annual Workshop on Pharmaceutical Outcomes Research, October 2002, Newport, RI
14. Golan Y, Jacobus NV, McDermott LA, Supran S, Hecht DW, Goldstein E, Venezia R, Harrell L, Jenkins S, Rihs J, Pierson C, Gorbach SL, Finegold S, Snyderman DR: Emergence of fluoroquinolone resistance among Bacteroides fragilis Group. The 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 2002, San Diego, CA
15. Doron S, El Gamal H, Tanius M, Barefoot L, Blunt K, Bloom J, Gamson K, Snyderman LK, Einekave E, Snyderman DR, Golan Y: The effect of gown use on compliance with handwashing. The 13th Annual Scientific Meeting of The Society for Healthcare Epidemiology of America (SHEA), April 2003, Arlington, Va.
16. Golan Y, Barefoot L, McDermott LA, Jacobus NV, Blunt K, Snyderman DR: The Effect of clindamycin resistance in Bacteroides species on outcomes of intra-abdominal infections. The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 2003, Chicago, IL.
17. McGovern B, Lopez M, Golan Y, Lawton A, Moore G, Pratt D, Epstein M, Knox T: Absolute CD4 T-cell subsets are decreased in HIV-seronegative patients with cirrhosis. The 41st Annual Meeting of the Infectious Disease Society of America (IDSA), October 2003, San Diego, Ca.
18. McGovern B, Lopez M, Golan Y, Lawton A, Moore G, Pratt D, Epstein M, Knox T: Absolute CD4 T-cell subsets are decreased in HIV-seronegative patients with cirrhosis. 54th Annual Meeting of The American Association for the Study of Liver Diseases. October 2003, Boston, MA
19. Golan Y, Scheib R, McGowan K, Stone D, Quirk J, Barefoot L, Y Carmeli Y: The impact of a community intervention program on management of HIV-infected inner-city patients. 50th International AIDS Conference, July 2004, Bangkok, Thailand
20. Jacobus NV, McDermott LA, Golan Y, Ruthazer R, Hecht DW, Finegold SM, Goldstein EJC, Harrell L, Jenkins S, Pierson C, Rihs J, Venezia R, Snyderman DR: US Survey on the susceptibility of B. fragilis group, Report: 2002-2003. Anaerobe Conference, July 2004, Annapolis MD,
21. Golan Y, Barefoot L, McDermott L, Snyderman DR: Risk Factors (RF) for Fluoroquinolone (FQ) Resistance in Bacteroides Species. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 2004, Washington DC.
22. Liddicoat RV, Zheng H, Golan Y, Internicola J, Rubinstein EP, Freedberg KA, Walensky RP: The high acceptance rate of routine voluntary HIV testing in a Massachusetts prison. Society of General Internal Medicine Conference 2005.
23. Golan Y, Russo R, Lamp KC, and Friedrich LV: Successful Treatment of Catheter-related Bacteremia (CRB) with Daptomycin (DAP): Report from a Registry: The 43rd Annual Meeting of the Infectious Disease Society of America (IDSA), October 2005, San Francisco, CA.
24. Golan Y, Snyderman DR, and the Bacteroides Resistance Group: Trends of Antibiotic Resistance in Bacteroides Isolated from the Female Genital Tract: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), December 2005, Washington DC
25. Golan Y, McDermott L, Perry L, Snyderman DR: Declining Linezolid Activity among MRSA Bacteremia Isolates. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 2006, San Francisco, CA
26. Golan Y, Baez-Giangreco C, O'Sullivan C, Snyderman DR: Trends in Vancomycin Susceptibility among Consecutive MRSA Bacteremia Isolates. The 44th Annual Meeting of the Infectious Disease Society of America (IDSA), October 2006, Toronto, Canada
27. Chow J, Golan Y, Ruthazer R, Lichtenberg D, Young J, Hadley S: Risk Factors for Non-albicans Candidemia in the Intensive Care Unit. Society of Critical care Medicine (CCM), the 36th Critical Care Congress, February 2007, Orlando, FL
28. Lamp K, Friedrich L, Golan Y, Couch K: Outcomes Associated with Daptomycin Use for Catheter-Related Bacteremia: Results from a Registry. 9th International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections, June 2007, Heidelberg, Germany
29. Marchaim D, Kaye K, Fowler V, Chawla V, Golan Y, Karchmer AW, Carmeli Y: Risk Factors for Mortality among Patients with Methicillin Resistant Staphylococcus aureus (MRSA) Bacteremia: The Role of Delay in Appropriate Antimicrobial Therapy (DAAT). The 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 2007, Chicago, IL
30. Chow JK, Golan Y, Ruthazer R, Karchmer AW, Lichtenberg D, Chawla V, Young J, Hadley S: Risk Factors for albicans and Non-albicans Candidemia in the Intensive Care Unit. The 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 2007, Chicago, Ill.
31. Drees M, Schmid CH, Barefoot L, Hansjosten K, Vue PM, Cronin M, Nasraway SA, Golan Y; Prior Environmental Contamination Increases Risk for Acquisition of Vancomycin-Resistant Enterococci. The 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 2007, Chicago, IL
32. Chow JK, Golan Y, Ruthazer R, Karchmer AW, Lichtenberg D, Chawla V, Young J, Hadley S: Factors Associated with Non-albicans vs. albicans Candidemia in the ICU. The 45th Annual Meeting of the Infectious Disease Society of America (IDSA), Oct. 2007, San Diego, CA
33. Torrez-Madriz G, Lawrence K, Golan Y: Breakthrough Clostridium difficile-associated diarrhea (CDAD) in patients receiving rifaximin to prevent hepatic encephalopathy (HE). The 45th Annual Meeting of the Infectious Disease Society of America (IDSA), Oct. 2007, San Diego, CA
34. Chawla V, Barefoot L, Perry L, Snyderman DR, Golan Y: Absence of Night Shift in the Microbiology Laboratory (ML): Impact on Processing and Reporting of MRSA-Positive Blood Cultures. The 45th Annual Meeting of the Infectious Disease Society of America (IDSA), Oct. 2007, San Diego, CA
35. Golan Y, Polgreen P, Beekmann S, Kent DM: Use or preserve? How practice patterns impact upon markets for new and improved antibiotics (abx). The 45th Annual Meeting of the Infectious Disease Society of America (IDSA), Oct. 2007, San Diego, CA

## CURRICULUM VITAE

Yoav Golan MD MS FIDSA

36. Drees M, Schmid CH, Barefoot L, Hansjosten K, Vue PM, Cronin M, Nasraway SA, Golan Y: Anti-anaerobic antibiotics did not increase risk for room contamination in patients colonized with vancomycin-resistant Enterococci. Annual Meeting of the Society of Healthcare Epidemiology in America (SHEA) April 2008, Philadelphia, PA
37. Oxman DA, Chow J, Frendl G, Hadley S, Marty F, Hershkowitz S, Ireland P, Lichtenberg D, Tsai K, Golan Y: Risk factors for reduced-susceptibility (RS) to fluconazole (F) among patients with Candidemia. The American Thoracic Society Conference (ATC) 2008.
38. Golan Y, Horth B, McDermott L, Weiner S, Barnewolt B, Snyderman DR: Rates of moxifloxacin (moxi) Resistance among *Bacteroides* spp. (BS) Isolated in the Emergency Department (ED) and its Relation to Prior Antibiotic Exposure. The 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 2008, Washington, DC.
39. Hjalmarson KI, Craven DE, Snyderman DR, Golan Y: The use of daptomycin in Vancomycin-Resistant *Enterococcus* bacteremia: a single center experience. The 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Oct 2008, Washington, DC.
40. Golick MV, Lawrence KR, Golan Y: High dose daptomycin in Patients with Severe Infections: efficacy and tolerability. The 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 2008, Washington, DC.
41. Louie TJ, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Shue YK, Sears P, Miller MA: A randomized controlled trial of OPT-80 versus vancomycin in *Clostridium difficile* infection. European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 2009 Helsinki, Finland.
42. Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK, Louie TJ: OPT-80 versus vancomycin in *Clostridium difficile* infection: Results of a randomized clinical trial. Digestive Diseases Week (DDW) May 30-June 04, 2009; Chicago, IL
43. Golan Y, Mullane KM, Miller MA, Weiss K, Lentnek A, Sears P, Shue YK, Gorbach SL, Louie TJ: Low recurrence rate among patients with *C. difficile* infection treated with Fidaxomicin. The 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 2009, San Francisco, CA.
44. Drees M, Snyderman DR, Griffith J, Vue PM, Enekave E, Epstein S, Nasraway SA, Golan Y: Gown Use Does Not Decrease Transmission of Methicillin-resistant *Staphylococcus aureus* (MRSA) and Vancomycin-resistant Enterococci (VRE) if Hand Hygiene Compliance is Suboptimal. The 47th Annual Meeting of the Infectious Disease Society of America (IDSA), Oct. 2009, Philadelphia, PA
45. Pollack T, Karchmer AW, Snyderman DR, Chawla V, Carmeli Y, Golan Y: Vancomycin Exposure and its Relation to Mortality from Methicillin-Resistant *Staphylococcus aureus* (MRSA) Bacteremia are affected by Severity of Illness. The 47th Annual Meeting of the Infectious Disease Society of America (IDSA), Oct. 2009, Philadelphia, PA
46. Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Sears P, Shue YK, Louie TJ: Age, Serum Albumin, and Leukocytosis/Fever Predict Clinical Outcomes of *Clostridium difficile* Infection Treated with Fidaxomicin and Vancomycin. The 47th Annual Meeting of the Infectious Disease Society of America (IDSA), Oct. 2009, Philadelphia, PA
47. Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Sears P, Shue YK, Louie TJ: Faster Time to Resolution of Diarrhea with Fidaxomicin vs. Vancomycin in Patients with *Clostridium difficile* Infection. The 47th Annual Meeting of the Infectious Disease Society of America (IDSA), Oct. 2009, Philadelphia, PA
48. Mullane KM, Miller MA, Weiss K, Lentnek A, Golan Y, Sears P, Shue YK, Louie TJ: Effect of Concomitant Antibiotics on Treatment of *Clostridium difficile* Infection with Fidaxomicin or Vancomycin. The 47th Annual Meeting of the Infectious Disease Society of America (IDSA), Oct. 2009, Philadelphia, PA
49. Golan Y, McDermott L, Snyderman DR: Trends in ceftobiprole susceptibility among 2001-2008 consecutive methicillin-resistant *Staphylococcus aureus* (MRSA) blood isolates. European Conference of Clinical Microbiology and Infectious Diseases (ECCMID), Vienna April 2010
50. Golan Y, Harrison D, Fahrback K: An echinocandin vs. a comparator antifungal (CAF) in *Candida* blood-stream infections (CBSI): a metaanalysis. European Conference of Clinical Microbiology and Infectious Diseases (ECCMID), Vienna April 2010
51. Snyderman DR, Jacobus NV, McDermott LA, Ruthazer R, Golan Y, Hecht DW, Goldstein EJ, Harrell L, Jenkins S, Newton D, Rosenblatt JE: Increasing resistance of carbapenems to *Bacteroides fragilis* and related species: a US survey, 2006-2008. European Conference of Clinical Microbiology and Infectious Diseases (ECCMID), Vienna April 2010
52. Golan Y: The problems with pre-emptive antifungal therapy studies are... Invited Lecture, The 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 2010, Boston, MA.
53. Chow JK, Goetz JD, Karchmer AW, Golan Y: Predictive Model for the Development of Candidemia in the ICU Within 1 Week. The 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 2010, Boston, MA.
54. Miller M, Louie T, Mullane K, Weiss K, Lentnek A, Golan Y, Robinson J, Sears P: Correlation of the ATLAS bedside scoring system and its components with cure and recurrence of *Clostridium difficile* infection (CDI). The 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 2010, Boston, MA.
55. Miller M, Louie T, Mullane K, Weiss K, Lentnek A, Golan Y, Robinson J, Sears P: Categorization of Patients in a Large Multicenter Study of *Clostridium Difficile* Infection (CDI) Using the ATLAS Bedside Scoring System, and Correlation with Both Cure and Recurrence. The 48th Annual Meeting of the Infectious Disease Society of America (IDSA), Oct. 2010, Vancouver, Canada
56. Golan Y, Micek S, Kollef M: Candidal vs. Bacterial severe sepsis in the ICU: The number-needed-to-treat. The 48th Annual Meeting of the Infectious Disease Society of America (IDSA), Oct. 2010, Vancouver, Canada.
57. Louie T, Miller M, Mullane K, Weiss K, Lentnek A, Golan Y, Robinson J, Sears P: Age And Clinical Outcomes Of *Clostridium difficile* Infection (CDI) In A Randomized Clinical Trial (RCT) And Effects of Initial Treatment With Fidaxomicin (FDX) versus Vancomycin (VAN). The 48th Annual Meeting of the Infectious Disease Society of America (IDSA), Oct. 2010, Vancouver, Canada
58. Golan Y, Mullane K, Louie T, Miller M, Weiss K, Lentnek A, Kean Y, Shue YK, Gorbach SL: Immunosuppression and the risk of death, cure rates and disease recurrence among patients with *Clostridium difficile* infection (CDI). European Conference of Clinical Microbiology and Infectious Diseases (ECCMID), Milan, Italy, May 7-10, 2011
59. Golan Y, Louie T, Weiss K, Mullane K, Kean Y, Lentnek A, Gorbach SL, Miller M: *Clostridium difficile* recurrence (CDR), alcohol consumption, and the effect of fidaxomicin vs vancomycin. European Conference of Clinical Microbiology and Infectious Diseases (ECCMID), Milan, Italy, May 7-10, 2011
60. Golan Y, Louie T, Miller M, Mullane K, Weiss K, Lentnek A, Robinson J, Sears P, Shue YK, Gorbach SL: Risk of Recurrence and Time to Recurrence Following Treatment of *Clostridium difficile* Infection: Patient Characteristics and the Differential Effect of Fidaxomicin vs. Vancomycin. Digestive Disease Week (DDW), May 8-10, 2011, Chicago, IL

## CURRICULUM VITAE

Yoav Golan MD MS FIDSA

61. Mullane K, Golan Y, Crook D, Cornely O, Miller M, Louie T, Gorbach SL: Renal Impairment and Response to Fidaxomicin versus Vancomycin in Patients with *Clostridium difficile* Infection. Submitted to: The 49th Annual Meeting of the Infectious Disease Society of America (IDSA), Chicago, IL
62. Golan Y, Sura M, Mohammed A, Martin S, Gabardi S: Micafungin treatment and eradication of candiduria among hospitalized patients. The 49th Annual Meeting of the Infectious Disease Society of America (IDSA), Chicago, IL
63. Alraddadi B, Epstein L, Snyderman DR, Golan Y: Recurrence of *C. difficile* infection (CDI): A risk-stratified analysis of Fidaxomicin vs Vancomycin. ID Week 2012, San Diego, CA.
64. Louie TJ, Golan Y, Mullane KM, Miller MA, Crook DW, Lentnek A, Kean Y, and Gorbach SL: Optimal Treatment Duration of *Clostridium difficile* Infection (CDI) With Vancomycin or Fidaxomicin is > Nine Days. ID Week 2012, San Diego, CA
65. Golan Y, McDermott L, Snyderman DR: Trends of Ceftaroline (CPT) Activity Among Consecutive Methicillin-resistant *Staphylococcus aureus* (MRSA) Blood Isolates and Correlation with Vancomycin (VAN) Activity. ID Week October 2013, San Francisco, CA
66. Beaulac KR, Nierenberg N, Doron S, Golan Y: Ceftaroline Fosamil (CFT) in patients with Persistent Methicillin-Resistant *S. aureus* (MRSA) Bacteremia. ID Week October 2013, San Francisco, CA
67. Weston A, Golan Y, Holcroft C, Snyderman DR: The Efficacy of Daptomycin vs. Vancomycin for MRSA Bloodstream Infection in Patients with Impaired Renal Function. ID Week October 2013, San Francisco, CA
68. Golan Y, Ruthazer R, Ding M, Zhao Q, Huang XY: Mortality and Hospital Length of Stay (HLOS) among Patients with Community-Acquired Pneumonia (CAP): A Propensity Score-Matched Analysis of Ceftaroline fosamil (CPT-F)-Treated vs. Ceftriaxone-treated patients. ECCMID, Barcelona, Spain, May 2014
69. Golan Y, Ding M, Zhao Q, Jandourek A, Huang XY: Ceftaroline fosamil (CPT-F) in bacteremia associated with Community-Acquired Pneumonia (CAP) or Acute Bacterial Skin and Skin Structure Infections (ABSSSI). ECCMID, Barcelona, Spain, May 2014
70. Johnson K, Gjini P, Bollinger S, Magro F, Husein S, Doron S, Snyderman DR, Golan Y: Alternative Causes of Diarrhea and clinical manifestations of *C. difficile* infection (CDI) among patients with a positive PCR and a negative toxin-detecting assay. ECCMID, Barcelona, Spain, May 2014
71. Acker W, Golan Y: Outcomes of *C. difficile* infection in patients with advanced liver disease and the effectiveness of fidaxomicin vs oral vancomycin in this patient population. IDWEEK, San Diego, CA, October 7-14, 2015
72. Gjini P, Wagner P, Lai K., Lee K., Golan Y: Factors Associated with High Risk for Multiple Recurrences of *C. difficile* Infection. ID WEEK, San Diego, CA, October 7-14, 2015
73. Upshaw JN, Margolis L, Patel AR, Golan Y, Vest AR, Arkun K, Kiernan MS, DeNofrio D: Disseminated Zygomycetes early after cardiac transplantation. IHSLT, Washington DC, USA, April 27-30, 2016.
74. Golan Y, Dubberke E, Hanson M, Liao J, Pedley A, Dorr M, Marcella C, Prabhu V: Bezlotoxumab (BZO) Decreases Recurrence and Is Associated With a Reduction in 30-Day *Clostridium difficile* Infection (CDI)-Associated Readmissions in Hospitalized Patients With CDI. ASM Microb, Boston MA June 2016
75. Mullane KM, Wilcox M, Golan Y, Murata Y, Shoemaker K, Kelly M, Pedley A, Dorr MB. Efficacy of Bezlotoxumab (bezlo) in Prevention of *C. difficile* infection Recurrence (rCDI) in Patients Receiving Concomitant Systemic Antibiotics (CAs). ID Week, New Orleans October 26-30, 2016.
76. Trucksis M, Baird I, Cornely OA, Golan Y, Hecht GA, Pardi DS, Pullman J, Polage CR, Wilcox MH, Bernardo P, Ford C, O'Brien E, Wortman J, Weston J, Henn M; An analysis of results from the first placebo-controlled trial of single-dose SER-109, an investigational oral Ecobiotic® drug to reduce the recurrence of *Clostridium difficile* infection (CDI). ECCMID, Vienna, Austria, April 22-25, 2017.
77. Golan Y, Birch T, Rizzardini G, Jensen E, Hanson ME, Gabryelski L, Guris D, Dorr MB; Efficacy of Bezlotoxumab Based on Timing of Administration Relative to Start of Antibacterial Therapy for *C. Difficile* Infection (CDI). ASM Microb, New Orleans, LA, June 1-5 2017.
78. Golan Y, Cloutier DJ, Komirenko AS, DS Cebrik, TR Keepers, KM Krause, Connolly LE, Wagenlehner FME: Improved Outcomes at Late Follow-up (LFU) with Plazomicin Compared with Meropenem in Patients with Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) in the EPIC Study. ID Week, San Diego, CA Sep 2017.
79. Golan Y, DuPont HL, Aldomiro F, Jensen EH, Hanson ME, Dorr MB: Bezlotoxumab (BEZ) for Prevention of *Clostridium Difficile* Infection (CDI) Recurrence (rCDI): Outcomes in Patients with Substantial Renal Impairment (SRI). ID Week, San Diego, CA Sep 2017.
80. Pierluigi V, Giamarellos-Bourboulis EJ, Humphries RM, Golan Y, Daikos GL, Azie N, Loutit J, Spindler E, Zhang S, Walsh TJ, Alexander EL. Meropenem-Vaborbactam versus Best Available Therapy for Carbapenem-Resistant Enterobacteriaceae Infections in TANGO II: Outcomes in Patients with Cancer. ECCMID, Madrid, Spain April 2018.
81. Golan Y, Cloutier DJ, Komirenko SA, Cebrik DS, Keepers TR, Krause KM, Connolly LE. Improved Outcomes at Late Follow-up with Plazomicin Compared With Meropenem in Patients With Complicated Urinary Tract Infection, Including Acute Pyelonephritis, in the EPIC Study. The 21<sup>st</sup> Annual MAD-ID Meeting, Orlando, Florida, May 9-12, 2018.
82. Golan Y, Tang Y, Mt-Isa S, Wan H, Teal V, Badshah C, Dadwal S. Impact of letermovir CMV prophylaxis on re-hospitalization rates following allogeneic hematopoietic cell transplantation. ECCMID, 2020 Paris, France April 2020 (Conference cancelled, Epub)
83. Diaz JG, McGregor JS, Ramani A, Lock J, Golan Y, Gonzalez PL. Dalbavancin in Osteomyelitis and Joint Infections: An Analysis From an Observational, Multicenter, Retrospective Cohort Study of the Real-World Use in Adult Patients. IDWEEK 2020
84. Meshulam N, Fisher A, Golan Y: Opioid treatment and outcomes of *Clostridioides difficile* infection (CDI). ECCMID 2021, Vienna, Austria

### Q. INVITED SPEAKER: Selected Lectures

1. Medical Grand rounds. Jordan Hospital, Plymouth MA, June 10th, 2003. Antibiotic resistance- a practical approach. Grand rounds at South Shore Hospital, MA, March 27th, 2003.
2. Grand rounds at Charlson Hospital, Fall River, MA, September 18th, 2003. The epidemiology and management of MRSA infections:
3. Grand Rounds, St. Lux Hospital, New Bedford, Massachusetts, October 3rd, 2003. Multiple resistant Gram negative bacteria: Extended spectrum-lactamases.
4. Infectious Diseases rounds, Roger Williams Hospital, Providence, RI, October 22nd, 2003. Infections by ESBL-producing Bacteria.
5. 38th American Society of Healthcare Pharmacists (ASHP) midyear conference, New Orleans, LA, December 9th, 2003. Transplant Mycology.

## CURRICULUM VITAE

Yoav Golan MD MS FIDSA

6. Medicine Grand Rounds. Framingham Metro West Hospital, Framingham, MA. May 2004. Infections by producers of Extended-spectrum beta lactamase.
7. Medicine grand rounds, St. Lux Hospital, New York, NY April 2005. Resistance Trends Among Gram Positive Pathogens and New Treatment Options.
8. St. John's Riverside Hospital. Hospital-wide grand rounds, Yonkers, NY, June 2005. Emerging issues in Gram positive infections.
9. Infectious diseases rounds, Jacobi hospital, Bronx, New York, September 2005. Emerging issues in Gram positive infections,
10. Grand rounds, Newton Wellesley Hospital, Newton, MA, June 2006. MRSA: current issues,
11. The Conference of the Southern Osteotomy Society, Portland ME, October 2006. The Emergence of Antibiotic Resistance Among Gram Positive Bacteria: Impact on Care and Patient Outcomes,
12. Infectious Diseases rounds, St. Barnabas Hospital, New York, October 2006. MRSA: an Update and Recent Results from the Endocarditis Trial.
13. IDSA 2006, Toronto, Canada, October 2006. Cost-effectiveness Analysis of Empiric Therapy of Invasive Candidiasis in the ICU
14. Meeting of the New Jersey Infectious Disease Society, May 2007. Advancements in the management of invasive fungal infections in high-risk patients.
15. Medical grand rounds, Boston VA Medical Center, February 2008. Early anti-Candida therapy strategies in the ICU.
16. Medical Grand Rounds. Milton Hospital, Milton, MA, February 2008. A Proactive Approach Against Herpes Zoster: Incorporation into Clinical Practice.
17. Surgery rounds, Binghamton General Hospital, Binghamton NY, March 2008. ICU candidemia: risk stratification and early treatment interventions. ICU
18. Grand rounds, Ellis Hospital, Schenectady NY, April 2008. Strategies for prediction and early therapy of invasive candidiasis.
19. Surgical grand rounds, Bay State Hospital, Springfield MA, September 2008. Strategies for early therapy of invasive candidiasis in the intensive-care unit.
20. Medical Rounds, Loyola Medical Center, Maywood, IL, September 2008. The Changing Face of Candidemia: The Cancer Patient.
21. Temple University Medical center, Medical Rounds, Philadelphia, PA, September 2008. The changing epidemiology of invasive Candida infections: strategies for early therapy.
22. Christiana Care Medical Center, Grand Rounds, Newark, DE, September 2008. Early treatment strategies for invasive candidiasis: emphasis on the critically-ill patient.
23. Grand Rounds, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, August 2009. Candida blood stream infections: the shift from the immunosuppressed to the ICU.
24. A series of 6 lectures, Pulmonology/ICU rounds, Shen Yang, Shanghai, Guangzhou, Huang Zhou, Beijing, China, August 2009. Invasive Candida Infections in the ICU: risk factors, changing epidemiology comparative effectiveness and early interventions.
25. A series of 10 National CME symposia. Miami, Atlanta, Houston, New York, Pittsburgh, Indianapolis, St. Louis, Phoenix, Las Vegas, Los Angeles. March and April, 2010. Invasive bacterial and fungal infections: encouraging guidelines-based management.
26. Hospital-wide grand rounds. Singapore General Hospital, Singapore. June 2010. Risk stratification among septic ICU Patients: prediction and management of invasive candidiasis
27. Medicine rounds. Tan Tock Seng Hospital. Singapore. June 2010. The changing epidemiology of invasive candida infections.
28. The 2nd Shanghai Oriental Respiratory Disease Forum. Shanghai, China, June 2010. Characterization of patients with Azole-nonsusceptible candidemia.
29. The 2nd Shanghai Oriental Respiratory Disease Forum. Shanghai, China, June 2010. Prediction of invasive candidiasis in ICU patients.
30. Medicine Grand Rounds. Royal Adelaide Hospital, Adelaide, Australia. June 2010. The emergence of invasive candida infections in the ICU: predictors and factors influencing patient outcomes.
31. Infectious Diseases Rounds, Alfred Hospital, Melbourne, Australia, June 2010. For invasive candidiasis: fluconazole, amphotericin or the echinocandins?
32. Peter Mac Cancer Centre, Melbourne, Australia. June 2010. ICU candida blood stream infections: Risk stratification and early treatment interventions. Hematology and Oncology Rounds,
33. Surgery and Critical Care Rounds. Bay State Medical Center. December 2010. An early management approach to the septic ICU patient with specific emphasis on invasive candidiasis.
34. The Chinese Society of Critical Care, Guangzhou, China, June 2011. Invasive Candidiasis in ICU patients: Contrasting the epidemiology in North America, Europe, and China- lessons learned and early interventions.
35. The Indian Society of Critical Care Medicine, Pune India. February 2012 Predicting Invasive Candidiasis in ICU patients.
36. Hospital-wide Grand Rounds, Medenta Medical Center, New Delhi, India, February 2012. Early prediction and management of invasive candidiasis in liver transplant patients.
37. Hospital-wide grand rounds, Singapore General Hospital, Singapore, February 2012. Antifungal prophylaxis to high-risk patients
38. Duke ID Rounds, Durham NC, March 13, 2012. An update on C. difficile epidemiology and management: focus on high risk populations.
39. The Annual Meeting of the Nebraska Infectious Diseases Society, April 26, 2012. An update on C. difficile infections.
40. Medical Grand Rounds, Westchester Medical Center, NY, May 9, 2012. New treatment options for MRSA: focus on pneumonia and skin infections. ICU candidemia: risk stratification and early treatment interventions- ICU/surgery Patients.
41. Grand Rounds, Ellis Hospital, Schenectady NY, May 18, 2013. CAP with focus on the emergence of S. aureus and reduced susceptibility to ceftriaxone
42. Grand Rounds, Naval Hospital, Groton CT, July 18, 2012. An update on adult immunizations.
43. Medical Grand Rounds, Buffalo General Hospital, July 19, 2012. An update on MRSA bacteremia endocarditis.
44. Rochester General Hospital, hospital-wide grand rounds, Rochester, NY, January 10, 2013. The changing epidemiology of infections by Gram-positive organisms: the relevance of vancomycin MIC creep. January 10, 2013
45. Critical Care Conference, Istanbul Turkey, January 2013. Infections by multi-drug-resistant Gram negative pathogens in the ICU- implications for patient care.

## CURRICULUM VITAE

Yoav Golan MD MS FIDSA

46. The Asia Pacific Critical Care Meeting, Kuala Lumpur, Malaysia, March 2013. Factors influencing the outcome of invasive fungal infections in immunocompetent patients and risk stratification to enable early therapy.
47. The Annual Meeting of the RI coalition of immunizations, Warwick RI, April 4, 2013. Updates Regarding Pneumococcal Disease in Adults
48. The Annual Meeting of the New Jersey Infectious Diseases Society, April 30, 2013. Prevention of C. difficile recurrence using risk-of-recurrence stratified strategies.
49. Medical Grand Rounds, New York Hospital Queens, May 24, 2013. Update of the management of infections by C. difficile with focus on risk-stratified approaches to prevent recurrent disease.
50. Tufts Medical Center: Hospital-wide grand rounds, May 31, 2013. Recent development in C difficile infections,
51. Asia Pacific Infectious Diseases Conference, Pattaya, Thailand, June 2013. Antifungal therapy in the ICU: from guidelines to practice.
52. Asia Pacific Infectious Diseases Conference, Pattaya, Thailand, June 2013. High risk invasive fungal infections in the ICU- Antifungal use-when and where.
53. GTC: ID World Summit 2014, 11th Anti-infective Partnering and Deal Making, Boston, MA July 7, 2013. Keynote lecture: Multi-drug resistant Gram negative infections.
54. Lawrence General Hospital, Lawrence, MA, September 10th, 2014. The emergence of C difficile as a major hospital pathogen and prevention strategies
55. The Thai ID Society Annual Meeting, Chiang Mai, Thailand, October 24, 2013. Prevention of invasive aspergillosis in high risk hematology patients
56. The Indian Society of Critical Care Medicine, Bhopal, India, October 26, 2013. Invasive candidiasis in the ICU patient.
57. BI Milton Hospital, Milton, MA, January 10, 2014. Influenza: an update on epidemiology and vaccinations
58. MetroWest Medical Center, Framingham, MA, February 10, 2014. Necrotizing fasciitis and deep soft tissue infections: the state of the art
59. The Australian Society of Antimicrobials Conference, Melbourne, Australia, February 22, 2014. Clostridium difficile- The Latest Hospital Scourge: Risk-Based Management Strategies with fidaxomicin
60. Carney Hospital, hospital-wide Grand Rounds, Boston, MA, March 26, 2014. Clostridium difficile: an Update
61. GTC: ID World Summit 2014, 11th Anti-infective Partnering and Deal Making, Boston, MA July 9, 2014. Keynote Lecture: Antibacterials- The Gap
62. Macrolide Meeting 2016, Harvard University, Cambridge MA, March 2016. Keynote Lecture: Desired characteristics and potential role for new-generation macrolides.
63. ASM Microb June 2017, New Orleans LA: Clinical Applications of New and Investigational Antimicrobials.
64. Asia Pacific Infectious Diseases Forum, June 2017 Bangkok, Thailand. Update on the management of complicated IAI and complicated UTI- focus on multi-drug-resistant Gram negative pathogens.
65. Global Infectious Diseases Initiative: First Inaugural Lecture: This is the right time! A unique opportunity to prevent the spread of healthcare infections and antibiotic resistance in Nigeria. July 7<sup>th</sup> 2017, Lagos, Nigeria.
66. Global Infectious Disease Form. XDR Gram negative infections: Medical and Health Economic Burden 15 – 17 November 2017, Madrid, Spain
67. Medicine Grand Rounds: Taxoma Medical Center, Dennison, TX: Clostridium difficile: an update on diagnosis and changing treatment guidelines. January 30 2018.
68. Medicine Grand Rounds: Backus Health System, Norwich, CT: Antimicrobial Stewardship- Concepts, Guidelines, and what is in the future. 1/19/18
69. CME Educational Series: Contagion Peer Exchange: Resistant Pseudomonas Aeruginosa in the ICU Peer Exchange. 1/8/18 NJ.
70. Re-Entering Antibacterial Discovery and Development Summit: Keynote Lecture - The Changing Environment and Challenges in Infections by Antibiotic-Resistant Pathogens. Oct 18-20, 2017 in Boston
71. ID WEEK Lecture: Clostridium difficile-Associated Diarrhea and Current Considerations for Treatment. October 7<sup>th</sup>, 2017 San Diego, CA.
72. PriMed East Conference: Pneumococcal vaccination: implications for the primary care provider: September 15<sup>th</sup>, 2017, Hynes Convention Center, Boston, MA.
73. Medical Grand Rounds, Option Care, St Cloud, MN: The Rising Tide of Gram-Negative Resistance. September 26<sup>th</sup>, 2017
74. Medicine Grand Rounds: C. difficile- the latest hospital scourge. August 4<sup>th</sup> 2017, Augusta, GA
75. The 22<sup>nd</sup> Meeting of the Hong Kong Infectious Diseases Society: The fight against the deadliest superbugs: a race against time!. March 17, 2018
76. The Annual Meeting of the European Society of Hospital Pharmacists: Shifting the paradigm in timing and choice of therapy for resistant Gram-negative Infections. Gothenburg, Sweden, March 22<sup>nd</sup>, 2018
77. The 30<sup>th</sup> Annual Conference of the Infectious Diseases Society of Taiwan (IDST): keynote lecture- the rising tide of antibiotic resistance: obstacles and options. Taipei, Taiwan, March 25<sup>th</sup>, 2018
78. ECCMID Lecture: Antimicrobial Selection in Patients at Risk for Resistant Gram-negatives: A Case Based Approach. Madrid, Spain, April 22<sup>nd</sup> 2018.
79. The Annual Lithuanian ID Society Meeting: Clostridium difficile the (not so) new hospital scourge. Palanga, Lithuania, June 7<sup>th</sup>, 2018
80. The Annual Meeting of the Mexico Society of critical Care and Pulmonology. Ventilator-associated pneumonia- the changing epidemiology with focus on the emerging antibiotic-resistance among Gram negatives. May 2018